Compliance to genomic test recommendations to guide adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer, in real‐life settings

BACKGROUND: Genomic tests are a useful tool for adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive (HR+), and human epidermal growth factor receptor 2‐negative (HER2−) breast cancer with intermediate prognostic factors. Real‐life data on the use of tests can help identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Hequet, D., Hajjaji, N., Charafe‐Jauffret, E., Boucrauta, A., Dalenc, F., Nicolai, V., Lopez, J., Tredan, O., Deluche, E., Fermeaux, V., Tixier, L., Cayre, A., Menet, E., Lerebours, F., Rouzier, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501273/
https://www.ncbi.nlm.nih.gov/pubmed/37409516
http://dx.doi.org/10.1002/cam4.6315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501273/
https://www.ncbi.nlm.nih.gov/pubmed/37409516
http://dx.doi.org/10.1002/cam4.6315

Ejemplares similares